TNF and interstitial lung disease: Our study evaluated both outcomes in a large cohort of RA patients exposed to biologic therapies and found no significant difference in the risk of ILD incidence between patients exposed to tocilizumab, rituximab, or abatacept compared with anti-TNFα therapies.